The first COPD patient has been dosed in a Phase 1b COPD trial testing Bambusa Therapeutics’ dual-target therapy BBT002.

REYKJAVIK, Iceland, June 11, 2025--(BUSINESS WIRE)--EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory ...

Mucolytic agents decrease mucus viscoelastic properties, improve mucociliary clearance and decrease sputum production and appear designed to provide symptomatic relief to mucus hypersecretion in COPD.

Although there is significant improvement in managing asthma and chronic obstructive pulmonary disease (COPD) diseases, there is still a strong need in controlling symptoms to prevent hospitalizations ...

Chronic obstructive pulmonary disease – COPD for short – is one of the most common diseases of the lung. It affects almost 300 million people worldwide, of which about three million die every year. A ...

Early identification and treatment of patients with COPD at risk of exacerbation are crucial for better outcomes. Single-inhaler triple therapy (SITT) users showed improved exacerbation rates and ...

Forbes contributors publish independent expert analyses and insights. I cover end-of-life care and dabble in the culture of medicine. Results from a new report published in the British Journal of ...

EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to ...

The free sulfhydryl group of metabolite I breaks the disulfide bridges of mucus glycoproteins, resulting in reduced sputum physical properties in patients with acute and chronic mucus hypersecretion.

EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to ...